^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tigatuzumab (CS-1008)

    i
    Associations
    News

    Trials

    Company:
    Daiichi Sankyo
    Drug class:
    TRAIL R2 agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer (NCT01033240)
    Phase 2
    Daiichi Sankyo, Inc.
    Completed
    Last update posted :
    04/08/2021
    Initiation :
    07/09/2010
    Primary completion :
    07/13/2012
    Completion :
    09/09/2013
    AFP
    |
    sorafenib • tigatuzumab (CS-1008)
    Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer (NCT01307891)
    Phase 2
    University of Alabama at Birmingham
    Completed
    Last update posted :
    10/26/2017
    Initiation :
    03/01/2011
    Primary completion :
    06/01/2016
    Completion :
    06/01/2017
    HER-2 • PGR
    |
    HER-2 amplification • HER-2 negative
    |
    albumin-bound paclitaxel • tigatuzumab (CS-1008)